Shots:

• Novartis will provide TNO155 at no cost while Mirati will sponsor the clinical study evaluating the combination therapy for solid tumors harboring KRAS G12C mutations and the companies will jointly share the development cost for the combination therapy
• The focus of the collaboration is to expand Mirati’s KRAS program with increasing the efficiency of MRTX849 and to provide other options for patients with KRAS G12C mutations having resistance to other therapies
• Mirati’s MRTX849 is a KRAS G12C inhibitor being evaluated in a Phase I/II clinical study for patients with KRAS G12C-positive tumors. Novartis’ TNO155 is a SHP2 inhibitor- inhibiting MAPK signaling and prevents growth of SHP2-expressing tumor cells

Click here to read full press release/ article | Ref: Mirati | Image: Twitter